A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK).
暂无分享，去创建一个
T. Powles | D. McLaren | S. Crabb | T. Powles | S. Chowdhury | R. Hawkins | K. Fife | P. Nathan | R. Jones | J. Larkin | C. Ralph | A. Webb | J. Dunlop | T. Geldart | J. Brown | L. Beltrán | C. Ackerman | E. Boleti | A. Bhal | Janet E. Brown | R. Hill | P. Hall | Robert Jones | J. Brown